ABSENTEEISM AND WORK DISABILITY ASSOCIATED WITH PSORIASIS AND PSORIATIC ARTHRITIS IN THE US
Author(s)
Orbai AM1, Reddy S2, Villacorta R3, Dennis N4, Peterson S3, Mesana L5, Chakravarty SD6, Pacou M4, Lin I3, Walsh J7
1Johns Hopkins Arthritis Center, Baltimore, MD, USA, 2NYU School of Medicine, New York, NY, USA, 3Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, USA, 4Amaris, Paris, France, 5Amaris, New York, NY, USA, 6Janssen Scientific Affairs, LLC, Horsham, PA, USA, 7University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, USA
Presentation Documents
OBJECTIVES : Absenteeism and work disability substantially contribute to the economic burden of psoriasis (PsO) and psoriatic arthritis (PsA). This study compared short-term disability and absenteeism among patients with PsO, PsA, and a control group of patients without PsO and PsA. METHODS : The IBM MarketScan Commercial Database and Health and Productivity Management Database screened three adult patient groups for work absenteeism and/or short-term disability between 01/01/2009 and 04/30/2019: 1) PsO: ≥1 inpatient or 2 outpatient diagnoses for PsO (none for PsA); 2) PsA: ≥1 inpatient or 2 outpatient diagnoses for PsA; 3) Control: no PsO or PsA diagnoses. The control group was matched 3:1 to PsO and PsA patients based on age, gender, and number of non-rheumatological comorbidities. Absenteeism, short-term disability loss and costs (in 2018 USD) were evaluated descriptively and through mixed models. RESULTS : 5,427 PsO and 914 PsA absentee-eligible and 32,624 PsO and 5,326 PsA short-term disability-eligible patients were matched to the control group. Mean age at baseline for absentee-eligible patients (47.2 years ± 9.9) and short-term disability-eligible patients (45.6 years ± 9.9) were comparable among the groups. Average costs from non-recreational work absences were $1,901, $1,649, and $1,427 per patient per year (PPPY) for the PsA, PsO, and control group, respectively. Compared to the control group at one year, these costs were significantly greater in the PsA (p<0.001) and PsO (p<0.001) groups. The one-year odds of short-term disability were significantly greater among patients with PsA compared to PsO (OR:1.47, 95%CI:1.33-1.61) and controls (OR:1.89, 95%CI:1.72-2.07). The average costs from short-term disability were $654, $444, and $349 PPPY for the PsA, PsO, and control group, respectively. CONCLUSIONS : Absenteeism and short-term disability were highest among patients with PsA and lowest among the control group. Effective treatments and medical care could help improve disease control and reduce work disability costs for employers.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PMU31
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Multiple Diseases